Drug
Part A Rpl554
Part A Rpl554: highest development phase Phase 2, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Part A: RPL554 NCT04027439 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Part A: RPL554 NCT04091360 | Phase 2 | COPD |
Latest
No recent events.
Follow Part A Rpl554 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.